Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.48 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL122293 | 1.00 | SLC22A12 (0.48) | SLC22A12ALPLSLC40A1PTGES2HTR6 | |
| SCHEMBL10952200 | 0.85 | ELANE (0.38) | SLC22A12ALPLSLC40A1PTGES2HTR6 | |
| SCHEMBL7865867 | 0.84 | TRPV4 (0.41) | SLC22A12ALPLSLC40A1PTGES2ELANE | |
| SCHEMBL6972429 | 0.82 | ALPL (0.47) | SLC22A12ALPLSLC40A1PTGES2HTR6 | |
| SCHEMBL3528957 | 0.82 | ELANE (0.60) | SLC22A12ALPLSLC40A1PTGES2HTR6 | |
| SCHEMBL16835442 | 0.82 | ELANE (0.36) | SLC22A12ALPLSLC40A1PTGES2HTR6 | |
| SCHEMBL6039108 | 0.81 | SLC22A12 (0.48) | SLC22A12ALPLSLC40A1PTGES2HTR6 | |
| SCHEMBL2646108 | 0.81 | ALPL (0.46) | SLC22A12ALPLSLC40A1PTGES2HTR6 | |
| SCHEMBL10646541 | 0.81 | SLC22A12 (0.48) | SLC22A12ALPLSLC40A1PTGES2HTR6 | |
| SCHEMBL645001 | 0.81 | ALPL (0.46) | SLC22A12ALPLSLC40A1PTGES2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | disclosed |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2024217563-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-24 | — | — | WO | disclosed |
| CN-118556053-A | Lysine acetyl transferase 6A (KAT 6A) inhibitor and application thereof | 英矽智能科技知识产权有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-117915903-A | Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof | 佛罗里达大学研究基金会公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-114497741-B | High-voltage electrolyte and lithium ion battery | 山东海科创新研究院有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-4259118-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | The Scripps Research Institute (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-113651766-B | Isoxazole sulfonamide compound with BRD4 inhibitory activity, and preparation method and application thereof | 泰州职业技术学院 | 2023-08-18 | — | — | CN | disclosed |
| CN-116239591-A | (4R) -sulfonamido-L-prolinamide compound, preparation method, application and pharmaceutical composition thereof | 嘉兴学院 | 2023-06-09 | — | — | CN | disclosed |
| CN-112110898-B | Synephrine sulfonylation derivative and intermediate, preparation method and application thereof | 西南大学 | 2022-07-05 | — | — | CN | disclosed |
| WO-2022125989-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | SCRIPPS RESEARCH INSTITUTE, THE (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-114497741-A | High-voltage electrolyte and lithium ion battery | 山东海科创新研究院有限公司 | 2022-05-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383904-A1 | HETEROCYCLIC COMPOUNDS | MAGI3, MAG, MAGT1 | SLC22A12 4568/4885ALPL 1477/4885SLC40A1 4025/4885 |
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | OPRM1, CYP1A1, CYP3A4 | SLC22A12 1699/4885ALPL 4412/4885SLC40A1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.